SCHEMBL22930440

SCHEMBL22930440

Nc1ncnc2[nH]cc(-c3ccc(NC(=O)c4ccccc4)cc3)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.57
PIK3CA P42336 1/20 0.57
PIK3CB P42338 1/20 0.57
PIK3CG P48736 1/20 0.57
PRKDC P78527 1/20 0.57
KDR P35968 4/20 0.56
FLT3 P36888 4/20 0.56
KIT P10721 1/20 0.56
ROCK2 O75116 3/20 0.53
MAP4K4 O95819 3/20 0.53
CLK4 Q9HAZ1 3/20 0.53
GSK3B P49841 2/20 0.53
HIPK2 Q9H2X6 2/20 0.53
IRAK4 Q9NWZ3 2/20 0.53
CDC7 O00311 1/20 0.53
PIM1 P11309 1/20 0.53
PRKACA P17612 1/20 0.53
CDK2 P24941 1/20 0.53
PTPN1 P18031 3/20 0.51
AXL P30530 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29546594 0.83 NPC1 (0.56) FLT3ROCK2MAP4K4CLK4GSK3B
SCHEMBL7021288 0.80 LRRK2 (0.63) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL3128213 0.79 RIPK1 (0.67) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13861829 0.79 KDR (0.79) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL18044676 0.77 AXL (0.47) PIK3CDPIK3CAPIK3CBPIK3CGFLT3
SCHEMBL18044648 0.76 AXL (0.52) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL7005295 0.75 KDR (0.63) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL23917432 0.75 LRRK2 (0.50) KDRFLT3ROCK2MAP4K4CLK4
SCHEMBL29552165 0.75 NUDT14 (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL410257 0.75 NUDT14 (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-01-19 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10905768-B1 Heterocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION CRBN, MDM2, STUB1 PIK3CD 2674/4885PIK3CA 2777/4885PIK3CB 2447/4885
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A PIK3CD 3419/4885PIK3CA 3548/4885PIK3CB 3412/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A PIK3CD 3419/4885PIK3CA 3548/4885PIK3CB 3412/4885
US-10905768-B1 Heterocyclic degronimers for target protein degradation CRBN, MDM2, STUB1 PIK3CD 2674/4885PIK3CA 2777/4885PIK3CB 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.